• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points

    3/14/22 12:08:27 PM ET
    $DB
    $KC
    $MRNA
    $NKTR
    Major Banks
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $DB alert in real time by email

    The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday.

    The Dow traded up 0.61% to 33,143.88 while the NASDAQ fell 1.13% to 12,698.26. The S&P also fell, dropping, 0.05% to 4,202.22.

    Also check this: Meta Platforms And 4 Other Stocks Sold By Insiders


    Leading and Lagging Sectors


    Financials shares climbed by 2.8% on Monday. Meanwhile, top gainers in the sector included Deutsche Bank Aktiengesellschaft (NYSE:DB), up 11% and Sculptor Capital Management, Inc. (NYSE:SCU) up 13%.


    In trading on Monday, energy shares fell by 2.5%.


    Top Headline


    Russia sought China's military equipment to support its invasion of Ukraine, Financial Times reported citing U.S. officials. The U.S. looks to caution its allies against China's possible assistance to Russia.


    Equities Trading UP


    Volt Information Sciences, Inc. (NYSE:VOLT) shares shot up 95% to $5.89 after the company announced it would be acquired for $6 per share.


    Shares of Turquoise Hill Resources Ltd. (NYSE:TRQ) got a boost, shooting 33% to $26.69 after Rio Tinto proposed to acquire the company at C$34 per share.


    Moderna, Inc. (NASDAQ:MRNA) shares were also up, gaining 18% to $163.30 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

     


    Equities Trading DOWN

    Nektar Therapeutics (NASDAQ:NKTR) shares tumbled 55% to $4.7950 after the company's Phase 3 PIVOT trial did not meet its primary endpoint.


    Shares of Kingsoft Cloud Holdings Limited (NASDAQ:KC) were down 33% to $3.31. JP Morgan downgraded Kingsoft Cloud from Neutral to Underweight and announced a $3.5 price target.


    Waitr Holdings Inc. (NASDAQ:WTRH) was down, falling 32% to $0.3100 after the company on Friday reported Q4 earnings, posting a year-over-year decline in revenue.


    Also check out: Executives Buy Over $1.5M Of 4 Penny Stocks


    Commodities

    In commodity news, oil traded down 8.7% to $99.83, while gold traded down 1.3% to $1,959.10.


    Silver traded down 3.2% Monday to $25.325 while copper fell 2.2% to $4.5245.



    Euro zone

    European shares were higher today. The eurozone’s STOXX 600 rose 1.44%, London’s FTSE 100 rose 0.56%, while Spain’s IBEX 35 Index rose 1.52%. The German DAX gained 2.66%, French CAC 40 gained 2.04% and Italy’s FTSE MIB Index gained 1.96%.

    French current account deficit declined to EUR 1.79 billion in January from EUR 7.04 billion in the prior month, while trade deficit shrank to EUR 8.03 billion from EUR 11.39 billion. Wholesale price inflation in Germany increased 16.6% year-over-year in February.


    Economics


    There were no major US economic releases Monday.

    Check out this: Insiders Buy More Than $80M Of 3 Stocks

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 81,174,670 cases with around 993,810 deaths. India confirmed a total of at least 42,993,490 cases and 515,900 deaths, while Brazil reported over 29,368,770 COVID-19 cases with 655,130 deaths. In total, there were at least 458,633,270 cases of COVID-19 worldwide with more than 6,066,830 deaths.

    Get the next $DB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DB
    $KC
    $MRNA
    $NKTR

    CompanyDatePrice TargetRatingAnalyst
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    Kingsoft Cloud Holdings Limited
    $KC
    9/16/2025$21.00Buy
    Deutsche Bank
    Kingsoft Cloud Holdings Limited
    $KC
    9/9/2025Neutral → Buy
    BofA Securities
    More analyst ratings

    $DB
    $KC
    $MRNA
    $NKTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DB
    $KC
    $MRNA
    $NKTR
    SEC Filings

    View All

    SEC Form 424B5 filed by Nektar Therapeutics

    424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)

    2/10/26 4:24:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    2/10/26 4:21:41 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-N filed by Deutsche Bank AG

    F-N - DEUTSCHE BANK AKTIENGESELLSCHAFT (0001159508) (Subject)

    2/10/26 3:43:44 PM ET
    $DB
    Major Banks
    Finance

    $DB
    $KC
    $MRNA
    $NKTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DB
    $KC
    $MRNA
    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

    SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering. The shares of common stock are being sold at a public offering price of $58.00 per share and the pre-funded warrants to purchase are being sold at a public offering price of $57.9999 per pre-funded warrant, wh

    2/11/26 10:23:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics Announces Proposed Public Offering

    SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $300,000,000 of its shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar. In addition, Nektar intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock at the pu

    2/10/26 4:05:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

    71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response rates Favorable safety profile consistent with previously reported results for rezpegaldesleukin Durability of maintained response rates supports advancement to pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing Data validate novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator Confere

    2/10/26 7:00:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DB
    $KC
    $MRNA
    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief R&D Officer Zalevsky Jonathan sold $137,936 worth of shares (3,867 units at $35.67), decreasing direct ownership by 15% to 21,354 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    1/22/26 7:31:42 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 780 shares, increasing direct ownership by 2% to 43,872 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    1/6/26 4:36:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief R&D Officer Zalevsky Jonathan was granted 6,250 shares, increasing direct ownership by 33% to 25,221 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    12/23/25 6:01:49 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DB
    $KC
    $MRNA
    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kingsoft Cloud upgraded by Goldman with a new price target

    Goldman upgraded Kingsoft Cloud from Neutral to Buy and set a new price target of $15.60

    2/11/26 7:42:03 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DB
    $KC
    $MRNA
    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Kingsoft Cloud Announces Resignation of Executive Director and Chief Financial Officer

    BEIJING, June 11, 2025 /PRNewswire/ -- The board (the "Board") of directors (the "Director(s)") of Kingsoft Cloud Holdings Limited (the "Company" or "Kingsoft Cloud") announces that Mr. He Haijian ("Mr. He") tendered his resignation as an executive Director and chief financial officer of the Company with effect from June 30, 2025, due to other personal commitments. Following the resignation of Mr. He, he also ceased to act as a member of the corporate governance committee of the Board. Mr. He confirmed that he has no claim against the Company and has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of shar

    6/11/25 12:32:00 PM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    Webull Appoints Walter Bishop to Board of Directors

    Mr. Bishop to serve as Independent Director and member of the Audit, Compensation and Nominating and Corporate Governance Committees ST. PETERSBURG, Fla., June 9, 2025 /PRNewswire/ --  Webull Corporation (NASDAQ:BULL) ("Webull" or the "Company"), the owner of the Webull online investment platform, today announced the appointment of Walter Bishop as independent director to its Board of Directors, effective June 8, 2025. Mr. Bishop will serve as a member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Mr. Bishop brings extensive

    6/9/25 8:45:00 AM ET
    $BULL
    $DB
    $INDI
    Investment Bankers/Brokers/Service
    Finance
    Major Banks
    Semiconductors

    $DB
    $KC
    $MRNA
    $NKTR
    Financials

    Live finance-specific insights

    View All

    New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

    71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response rates Favorable safety profile consistent with previously reported results for rezpegaldesleukin Durability of maintained response rates supports advancement to pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing Data validate novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator Confere

    2/10/26 7:00:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

    SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.  Conference Call The results will be provided in a mo

    2/9/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

    Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo Mean percent reduction in SALT scores at 36 weeks was 30% for both treatment arms versus 6% for placebo, achieving statistical significance (p<0.05) when excluding four patients that did not meet major study eligibility criteria at baseline Safety profile showed rezpegaldesleukin was well tolerated and was consistent with previously reported results Study results establish Phase 3 dose and support planned advancement to Phase 3 development in alopecia areata Conference call and webcast with management and alopecia areata exper

    12/16/25 7:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DB
    $KC
    $MRNA
    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

    SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 9:18:10 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care